DESTINY-Breast05: T-DXd vs T-DM1 in high-risk HER2+ early breast cancer - VJOncology Charles Geyer, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, discusses results from the Phase III DESTINY-Breast05 trial (NCT04622319), comparing...

Charles Geyer, MD, reports #DESTINYBreast05 results in HER2+ early BC.

💊 T-DXd > T-DM1 for iDFS & DFS
🧠 Reduced brain mets risk
⚖️ Manageable safety → potential new SoC

🎥 buff.ly/r3AwOkw

#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #Immunotherapy #HER2 #ESMO25 @myesmo.bsky.social